{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T16:08:12Z","timestamp":1787846892570,"version":"build-2784847793"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T00:00:00Z","timestamp":1725408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T00:00:00Z","timestamp":1725408000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research & Development, LLC","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-024-05958-8","type":"journal-article","created":{"date-parts":[[2024,9,4]],"date-time":"2024-09-04T03:35:12Z","timestamp":1725420912000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS Study"],"prefix":"10.1007","author":[{"given":"Weijun","family":"Fu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo-Mee","family":"Bang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honghui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kihyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Je-Jung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yafei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chor Sang","family":"Chim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Carson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Canchan","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,4]]},"reference":[{"key":"5958_CR1","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","volume":"186","author":"M de Weers","year":"2011","unstructured":"de Weers M, Tai YT, van der Veer MS, Bakker JM, Vink T, Jacobs DC, Oomen LA, Peipp M, Valerius T, Slootstra JW, Mutis T, Bleeker WK, Anderson KC, Lokhorst HM, van de Winkel JG, Parren PW (2011) Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol 186:1840\u20131848. https:\/\/doi.org\/10.4049\/jimmunol.1003032","journal-title":"J Immunol"},{"key":"5958_CR2","doi-asserted-by":"publisher","first-page":"3474","DOI":"10.1182\/blood.V124.21.3474.3474","volume":"124","author":"J van Lammerts","year":"2014","unstructured":"Lammerts van Bueren J, Jakobs D, Kaldenhoven N, Roza M, Hiddingh S, Meesters J, Voorhorst M, Gresnigt E, Wiegman L, Buijsse O, Andringa G, Overdijk MB, Doshi P, Sasser K, de Weers M, Parren PW (2014) Direct in vitro comparison of daratumumab with surrogate analogs of CD38 antibodies MOR03087, SAR650984 and Ab79. Blood 124:3474. https:\/\/doi.org\/10.1182\/blood.V124.21.3474.3474","journal-title":"Blood"},{"key":"5958_CR3","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1080\/19420862.2015.1007813","volume":"7","author":"MB Overdijk","year":"2015","unstructured":"Overdijk MB, Verploegen S, Bogels M, van Egmond M, Lammerts van Bueren J, Mutis T, Groen RW, Breij E, Martens AC, Bleeker WK, Parren PW (2015) Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. MAbs 7:311\u2013321. https:\/\/doi.org\/10.1080\/19420862.2015.1007813","journal-title":"MAbs"},{"key":"5958_CR4","doi-asserted-by":"publisher","first-page":"807","DOI":"10.4049\/jimmunol.1501351","volume":"197","author":"MB Overdijk","year":"2016","unstructured":"Overdijk MB, Jansen JH, Nederend M, Lammerts van Bueren J, Groen RW, Parren PW, Leusen JH, Boross P (2016) The therapeutic CD38 monoclonal antibody daratumumab induces programmed cell death via fcgamma receptor-mediated cross-linking. J Immunol 197:807\u2013813. https:\/\/doi.org\/10.4049\/jimmunol.1501351","journal-title":"J Immunol"},{"key":"5958_CR5","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","volume":"128","author":"J Krejcik","year":"2016","unstructured":"Krejcik J, Casneuf T, Nijhof IS, Verbist B, Bald J, Plesner T, Syed K, Liu K, van de Donk NWCJ, Weiss BM, Ahmadi T, Lokhorst HM, Mutis T, Sasser AK (2016) Daratumumab depletes CD38+ immune-regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood 128:384\u2013394. https:\/\/doi.org\/10.1182\/blood-2015-12-687749","journal-title":"Blood"},{"key":"5958_CR6","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1002\/cyto.a.23693","volume":"95","author":"HC Adams III","year":"2019","unstructured":"Adams HC III, Stevenaert F, Krejcik J, Van der Borght K, Smets T, Bald J, Abraham Y, Ceulemans H, Chiu C, Vanhoof G, Usmani SZ, Plesner T, Lonial S, Nijhof I, Lokhorst HM, Mutis T, van de Donk NWCJ, Sasser AK, Casneuf T (2019) High-parameter mass cytometry evaluation of relapsed\/refractory multiple myeloma patients treated with daratumumab demonstrates immune modulation as a novel mechanism of action. Cytometry A 95:279\u2013289. https:\/\/doi.org\/10.1002\/cyto.a.23693","journal-title":"Cytometry A"},{"key":"5958_CR7","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/s41375-020-0855-4","volume":"35","author":"T Casneuf","year":"2021","unstructured":"Casneuf T, Adams HC III, van de Donk NWCJ, Abraham Y, Bald J, Vanhoof G, Van der Borght K, Smets T, Foulk B, Nielsen KC, Rusbuldt J, Axel A, Lysaght A, Ceulemans H, Stevenaert F, Usmani SZ, Plesner T, Avet-Loiseau H, Nijhof I, Mutis T, Schecter JM, Chiu C, Bahlis NJ (2021) Deep immune profiling of patients treated with lenalidomide and dexamethasone with or without daratumumab. Leukemia 35:573\u2013584. https:\/\/doi.org\/10.1038\/s41375-020-0855-4","journal-title":"Leukemia"},{"key":"5958_CR8","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.3324\/haematol.2020.268656","volume":"106","author":"M Kinder","year":"2021","unstructured":"Kinder M, Bahlis NJ, Malavasi F, De Goeij B, Babich A, Sendecki J, Rusbuldt J, Bellew K, Kane C, van de Donk NWCJ (2021) Comparison of CD38 antibodies in vitro and ex vivo mechanisms of action in multiple myeloma. Haematologica 106:2004\u20132008. https:\/\/doi.org\/10.3324\/haematol.2020.268656","journal-title":"Haematologica"},{"key":"5958_CR9","doi-asserted-by":"publisher","first-page":"e447","DOI":"10.1016\/S2352-3026(20)30081-8","volume":"7","author":"SZ Usmani","year":"2020","unstructured":"Usmani SZ, Nahi H, Plesner T, Weiss BM, Bahlis NJ, Belch A, Voorhees PM, Laubach JP, van de Donk NWCJ, Ahmadi T, Uhlar CM, Wang J, Feng H, Qi M, Richardson PG, Lonial S (2020) Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials. Lancet Haematol 7:e447\u2013e455. https:\/\/doi.org\/10.1016\/S2352-3026(20)30081-8","journal-title":"Lancet Haematol"},{"key":"5958_CR10","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","volume":"387","author":"S Lonial","year":"2016","unstructured":"Lonial S, Weiss BM, Usmani SZ, Singhal S, Chari A, Bahlis NJ, Belch A, Krishnan A, Vescio RA, Mateos MV, Mazumder A, Orlowski RZ, Sutherland HJ, Blade J, Scott EC, Oriol A, Berdeja J, Gharibo M, Stevens DA, LeBlanc R, Sebag M, Callander N, Jakubowiak A, White D, de la Rubia J, Richardson PG, Lisby S, Feng H, Uhlar CM, Khan I, Ahmadi T, Voorhees PM (2016) Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial. Lancet 387:1551\u20131560. https:\/\/doi.org\/10.1016\/S0140-6736(15)01120-4","journal-title":"Lancet"},{"key":"#cr-split#-5958_CR11.1","doi-asserted-by":"crossref","unstructured":"Kumar SK, Moreau P, Bahlis N, Facon T, Plesner T, Orlowski RZ, Basu S, Nahi H, Hulin C, Quach H, Goldschmidt H, O'Dwyer M, Perrot A, Venner CP, Weisel K, Raje N, Tiab M, Macro M, Frenzel L, Leleu X, Wang G, Pei H, Krevvata M, Carson R, Borgsten F, Usmani SZ (2022) Daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone (Rd) alone in transplant ineligible patients with newly diagnosed multiple myeloma (NDMM): updated analysis of the phase 3 MAIA study. Presented at: 64th American Society of Hematology (ASH) Annual Meeting & Exposition","DOI":"10.1182\/blood-2022-163335"},{"key":"#cr-split#-5958_CR11.2","unstructured":"Kumar SK, Moreau P, Bahlis N, Facon T, Plesner T, Orlowski RZ, Basu S, Nahi H, Hulin C, Quach H, Goldschmidt H, O'Dwyer M, Perrot A, Venner CP, Weisel K, Raje N, Tiab M, Macro M, Frenzel L, Leleu X, Wang G, Pei H, Krevvata M, Carson R, Borgsten F, Usmani SZ (2022) Daratumumab plus lenalidomide and dexamethasone (D-Rd) versus lenalidomide and dexamethasone"},{"key":"#cr-split#-5958_CR11.3","unstructured":"(Rd) alone in transplant ineligible patients with newly diagnosed multiple myeloma (NDMM): updated analysis of the phase 3 MAIA study. Presented at: 64th American Society of Hematology (ASH) Annual Meeting & Exposition; December 10-13, 2022; New Orleans, LA, USA"},{"key":"5958_CR12","doi-asserted-by":"publisher","first-page":"e825","DOI":"10.1016\/S2352-3026(23)00217-X","volume":"10","author":"PM Voorhees","year":"2023","unstructured":"Voorhees PM, Sborov DW, Laubach J, Kaufman JL, Reeves B, Rodriguez C, Chari A, Silbermann R, Costa LJ, Anderson LD Jr., Nathwani N, Shah N, Bumma N, Efebera YA, Holstein SA, Costello C, Jakubowiak A, Wildes TM, Orlowski RZ, Shain KH, Cowan AJ, Dinner S, Pei H, Cortoos A, Patel S, Lin TS, Usmani SZ, Richardson PG (2023) Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial. Lancet Haematol 10:e825\u2013e837. https:\/\/doi.org\/10.1016\/S2352-3026(23)00217-X","journal-title":"Lancet Haematol"},{"key":"5958_CR13","doi-asserted-by":"publisher","first-page":"2079","DOI":"10.3324\/haematol.2018.194118","volume":"103","author":"A Spencer","year":"2018","unstructured":"Spencer A, Lentzsch S, Weisel K, Avet-Loiseau H, Mark TM, Spicka I, Masszi T, Lauri B, Levin MD, Bosi A, Hungria V, Cavo M, Lee JJ, Nooka AK, Quach H, Lee C, Barreto W, Corradini P, Min CK, Scott EC, Chanan-Khan AA, Horvath N, Capra M, Beksac M, Ovilla R, Jo JC, Shin HJ, Sonneveld P, Soong D, Casneuf T, Chiu C, Amin H, Qi M, Thiyagarajah P, Sasser AK, Schecter JM, Mateos MV (2018) Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR. Haematologica 103:2079\u20132087. https:\/\/doi.org\/10.3324\/haematol.2018.194118","journal-title":"Haematologica"},{"key":"5958_CR14","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1038\/s41375-020-0711-6","volume":"34","author":"NJ Bahlis","year":"2020","unstructured":"Bahlis NJ, Dimopoulos MA, White DJ, Benboubker L, Cook G, Leiba M, Ho PJ, Kim K, Takezako N, Moreau P, Kaufman JL, Krevvata M, Chiu C, Qin X, Okonkwo L, Trivedi S, Ukropec J, Qi M, San-Miguel J (2020) Daratumumab plus lenalidomide and dexamethasone in relapsed\/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 study. Leukemia 34:1875\u20131884. https:\/\/doi.org\/10.1038\/s41375-020-0711-6","journal-title":"Leukemia"},{"key":"5958_CR15","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/S0140-6736(19)32956-3","volume":"395","author":"MV Mateos","year":"2020","unstructured":"Mateos MV, Cavo M, Blade J, Dimopoulos MA, Suzuki K, Jakubowiak A, Knop S, Doyen C, Lucio P, Nagy Z, Pour L, Cook M, Grosicki S, Crepaldi A, Liberati AM, Campbell P, Shelekhova T, Yoon SS, Iosava G, Fujisaki T, Garg M, Krevvata M, Chen Y, Wang J, Kudva A, Ukropec J, Wroblewski S, Qi M, Kobos R, San-Miguel J (2020) Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. Lancet 395:132\u2013141. https:\/\/doi.org\/10.1016\/S0140-6736(19)32956-3","journal-title":"Lancet"},{"key":"5958_CR16","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.clml.2023.02.009","volume":"23","author":"W Fu","year":"2023","unstructured":"Fu W, Bang SM, Huang H, Kim K, Li W, An G, Lee JJ, Cai Z, Jin J, Wang Y, Lin TL, Chim CS, Qi M, Wang J, Lu X, Song Y, Jia B, Yang X, Liu W, Zhou T, Yin L, Li Y, Zhang R, Hou J, Wang J (2023) Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: the phase 3 OCTANS study. Clin Lymphoma Myeloma Leuk 23:446\u2013455.e4. https:\/\/doi.org\/10.1016\/j.clml.2023.02.009","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"5958_CR17","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"BGM Durie","year":"2006","unstructured":"Durie BGM, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K, Gertz M, Dimopoulos M, Westin J, Sonneveld P, Ludwig H, Gahrton G, Beksac M, Crowley J, Belch A, Boccadaro M, Cavo M, Turesson I, Joshua D, Vesole D, Kyle R, Alexanian R, Tricot G, Attal M, Merlini G, Powles R, Richardson P, Shimizu K, Tosi P, Morgan G, Rajkumar SV (2006) International uniform response criteria for multiple myeloma. Leukemia 20:1467\u20131473. https:\/\/doi.org\/10.1038\/sj.leu.2404284","journal-title":"Leukemia"},{"key":"5958_CR18","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, Kumar S, Hillengass J, Kastritis E, Richardson P, Landgren O, Paiva B, Dispenzieri A, Weiss B, Leleu X, Zweegman S, Lonial S, Rosinol L, Zamagni E, Jagannath S, Sezer O, Kristinsson SY, Caers J, Usmani SZ, Lahuerta JJ, Johnsen HE, Beksac M, Cavo M, Goldschmidt H, Terpos E, Kyle RA, Anderson KC, Durie BG, Miguel JF (2014) International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 15:e538\u2013e548. https:\/\/doi.org\/10.1016\/S1470-2045(14)70442-5","journal-title":"Lancet Oncol"},{"key":"5958_CR19","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1056\/NEJMoa1714678","volume":"378","author":"MV Mateos","year":"2018","unstructured":"Mateos MV, Dimopoulos MA, Cavo M, Suzuki K, Jakubowiak A, Knop S, Doyen C, Lucio P, Nagy Z, Kaplan P, Pour L, Cook M, Grosicki S, Crepaldi A, Liberati AM, Campbell P, Shelekhova T, Yoon SS, Iosava G, Fujisaki T, Garg M, Chiu C, Wang J, Carson R, Crist W, Deraedt W, Nguyen H, Qi M, San-Miguel J, ALCYONE Trial Investigators (2018) Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med 378:518\u2013528. https:\/\/doi.org\/10.1056\/NEJMoa1714678","journal-title":"N Engl J Med"},{"key":"5958_CR20","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1200\/JCO.2009.26.0638","volume":"28","author":"MV Mateos","year":"2010","unstructured":"Mateos MV, Richardson PG, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Spicka I, Petrucci MT, Palumbo A, Samoilova OS, Dmoszynska A, Abdulkadyrov KM, Schots R, Jiang B, Esseltine DL, Liu K, Cakana A, van de Velde H, San Miguel JF (2010) Bortezomib plus melphalan and prednisone compared with melphalan and prednisone in previously untreated multiple myeloma: updated follow-up and impact of subsequent therapy in the phase III VISTA trial. J Clin Oncol 28:2259\u20132266. https:\/\/doi.org\/10.1200\/JCO.2009.26.0638","journal-title":"J Clin Oncol"},{"key":"5958_CR21","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.3389\/fonc.2019.01513","volume":"9","author":"S Wang","year":"2019","unstructured":"Wang S, Xu L, Feng J, Liu Y, Liu L, Wang J, Liu J, Huang X, Gao P, Lu J, Zhan S (2019) Prevalence and incidence of multiple myeloma in urban area in China: a national population-based analysis. Front Oncol 9:1513. https:\/\/doi.org\/10.3389\/fonc.2019.01513","journal-title":"Front Oncol"}],"updated-by":[{"DOI":"10.1007\/s00277-024-06020-3","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T00:00:00Z","timestamp":1727049600000}}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05958-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-05958-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05958-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T19:03:09Z","timestamp":1727118189000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-05958-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,4]]},"references-count":23,"alternative-id":["5958"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-05958-8","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s00277-024-06020-3","asserted-by":"object"}]},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,4]]},"assertion":[{"value":"26 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2024","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00277-024-06020-3","URL":"https:\/\/doi.org\/10.1007\/s00277-024-06020-3","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with the ethical principles outlined in the Declaration of Helsinki and Good Clinical Practice and abided by all applicable regulatory requirements. The study protocol and amendments were reviewed and approved by independent ethics committees and institutional review boards at each participating site, and all patients provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"R.C. is an employee of Janssen Research & Development, LLC and owns stock or stock options. R.L. is an employee of Johnson & Johnson (China) Investment Ltd., Beijing Branch and owns stock or stock options. X.C. and C.C. are employees of Xian Janssen Pharmaceutical Ltd. and own stock or stock options. J.W. served as a member of the board of directors or advisory committees at AbbVie. All other authors have nothing to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}